- Previous Close
57.13 - Open
0.00 - Bid --
- Ask --
- Day's Range
57.20 - 57.20 - 52 Week Range
47.00 - 650.00 - Volume
0 - Avg. Volume
12 - Market Cap (intraday)
2.763B - Beta (5Y Monthly) -1.48
- PE Ratio (TTM)
-- - EPS (TTM)
-29.61 - Earnings Date May 8, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.
www.cassavasciences.comRecent News: SAVA.MX
View MorePerformance Overview: SAVA.MX
Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SAVA.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SAVA.MX
View MoreValuation Measures
Market Cap
1.31B
Enterprise Value
-1.14B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.93
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.18%
Return on Equity (ttm)
-17.19%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-24.34M
Diluted EPS (ttm)
-29.61
Balance Sheet and Cash Flow
Total Cash (mrq)
128.57M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-72.99M